Physician profile
Trevor Desouza
NPI 1972699205
$13,753.40
in general payments reported to CMS, 2019-2025
34 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,328 · 2020: $1,295 · 2021: $2,277 · 2022: $1,862 · 2023: $1,924 · 2024: $67.63.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,982 · Education: $8.93.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,982.47 |
| Education | $8.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $5,046.38 | 2019-2023 | Jornay Pm |
| Supernus Pharmaceuticals, INC. | $1,358.51 | 2019-2023 | Qelbree |
| Eisai INC. | $845.27 | 2019-2023 | |
| Neos Therapeutics, Lp | $772.45 | 2019-2023 | Cotempla Xr-Odt, Adzenys Xr-Odt |
| Tris Pharma INC | $734.73 | 2019-2024 | Dyanavel Xr, Quillivant, Quillichew Er |
| Ucb, INC. | $683.97 | 2019-2024 | Nayzilam, Briviact |
| Sunovion Pharmaceuticals INC. | $595.23 | 2019-2022 | |
| Sk Life Science, INC. | $464.17 | 2020-2023 | |
| Neurelis, INC. | $371.83 | 2021-2024 | Valtoco |
| Aquestive Therapeutics, INC. | $304.45 | 2019-2022 | |
| Rhodes Pharmaceuticals L.P. | $292.88 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $291.55 | 2019-2022 | |
| Arbor Pharmaceuticals, INC. | $268.86 | 2019-2022 | |
| Greenwich Biosciences, INC. | $251.80 | 2019-2021 | |
| Corium, LLC | $220.89 | 2022-2023 | Azstarys |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aprecia Pharmaceuticals, LLC | $174.82 | 2020-2023 | Spritam |
| Upsher-Smith Laboratories LLC | $172.40 | 2019-2020 | |
| Biogen, INC. | $116.75 | 2021 | |
| Travere Therapeutics, INC. | $106.05 | 2019-2023 | Cholbam |
| Adlon Therapeutics L.P. | $103.61 | 2019-2021 | |
| Jazz Pharmaceuticals INC. | $97.33 | 2022-2024 | Epidiolex |
| Acorda Therapeutics, INC | $95.31 | 2020 | |
| Sumitomo Pharma America, INC. | $78.45 | 2023 | Aptiom |
| Vertical Pharmaceuticals, LLC | $70.60 | 2019 | |
| Livanova USA, INC. | $67.68 | 2021-2022 | |
| Catalyst Pharmaceuticals, INC. | $45.19 | 2023 | Fycompa |
| Shire North American Group INC | $27.72 | 2019 | |
| Cognoa, INC. | $18.11 | 2022 | |
| Acadia Pharmaceuticals INC | $14.74 | 2023 | Daybue |
| Amneal Pharmaceuticals LLC | $13.08 | 2019 | |
| Allergan, INC. | $12.69 | 2019 | |
| Ptc Therapeutics, INC. | $12.61 | 2022 | |
| Novartis Pharmaceuticals Corporation | $11.85 | 2019 | |
| Piramal Critical Care | $11.44 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Trevor Desouza listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.